Agonistes du récepteur TGR5 dans le traitement du diabète et du syndrome métabolique (une étude prospective)

LILLE2-BU Santé-Recherche (593502101) / SudocSudocFranceF

Synthesis of a 200-member library of squaric acid N-hydroxylamide amides.

International audienceWe report here the parallel synthesis of 200 compounds based on squaric acid template. These compounds are obtained via a one-step solution-phase procedure starting from three squaric acid N-hydroxylamide esters precursors. The set of diverse reagents qualified (amines, anilines, amino-alcohols and amino-esters) makes this strategy suitable for the search of biologically active compounds. The library was screened on the zinc metalloenzyme ADAMTS-5 and hits with IC(50) in the range of 1-50 microM were identified

Alkylsquarates as key intermediates for the rapid preparation of original drug-inspired compounds.

International audienceMany natural privileged scaffolds contain a basic nitrogen atom, which often is a key element of pharmacophore and a chemically reactive centre as well. In our ongoing research program devoted to the design of targeted libraries based on acidic templates, we developed methods to convert privileged basic compounds -like natural alkaloids or drugs into acidic compounds. This conversion led to a profound alteration of the pharmacophore, without changing the overall shape and lipophilicity of the molecule. We expect such modifications to generate unexpected biological activities. Recently, we focused on derivatives of squaric acid, a vinylogous carboxylic acid. Two series were studied. First we describe a new, selective parallel synthesis of squaramic acids from a dissymmetric diester (3-tert-butoxy-4-ethoxy-cyclobut-3-en-1,2-dione). This efficient procedure avoids the synthesis of the undesired squaramides. Secondly we describe a microplate parallel synthesis (15 micromol-scale) of squaric acid hydroxamate amides from a squaric hydroxamate ester

Conception, synthèse et optimisation de modulateurs de l'Insulin-Degrading Enzyme et applications dans la maladie d'Alzheimer et le diabète

IDE (Insulin-Degrading Enzyme) est une métalloenzyme impliquée dans la dégradation de plusieurs peptides physiologiques. Des études lient la maladie d Alzheimer et le diabète de type II à IDE. En effet, parmi ses substrats, l enzyme compte le peptide Béta-amyloïde (A-Béta) responsable des plaques séniles de la maladie d'Alzheimer et l insuline régulant la glycémie. En 2006, l équipe du Pr. Tang a élucidé la structure cristallographique d'IDE qui a révélée que les substrats se lient à deux sites de l'enzyme : le site catalytique et un exosite. Grâce au criblage d'une chimiothèque, un composé a été découvert modulant de façon substrat-dépendante l'activité d'IDE. Ce composé a été cristallisé dans l enzyme: il peut se lier aux deux sites importants pour l hydrolyse des substrats: le site catalytique et l'exosite. Ce mode de liaison est cohérent avec la modulation substrat-dépendante observée. 80 analogues ont été synthétisés pour améliorer l activité et la perméation cellulaire. La modulation substrat-dépendante de la protéase permet d envisager l obtention d outils chimiques pour l étude de la fonction de cette enzyme et ouvre de nouvelles perspectives dans des pathologies où des substrats d IDE seraient impliqués. En parallèle, une réaction de Click Chemistry in situ a été effectuée et a permis l'identification de 32 ligands parmi 180 composés potentiels. 12 ont été resynthétisés et ont montré une activité inhibitrice de l'enzyme. Ces composés possèdent une fonction hydroxamate et se lient donc au site catalytique inhibant l'enzyme quelque soit son substrat. La co-cristallisation d'un des composés avec l'enzyme a confirmé ce mode de liaison.Insulin-Degrading Enzyme (IDE) is a zinc metalloprotease implicated in the clearance of numerous physiological peptides, in particular beta-amyloid (A[Béta]) peptide and insulin, respectively implicated in Alzheimer s disease and Diabetes.Tang et al. elucidated the X-ray structure of the human IDE and found that substrates have two anchoring sites : the catalytic site at the zinc and an exosite which are both key features for the binding and hydrolysis.In our laboratory, we have screened a 2080-compound library on the enzyme and found a 5 M hit inhibitor of A[Béta] hydrolysis. X-ray analysis of ligand-enzyme complexes, revealed that unexpectedly these compounds are either ligands of the catalytically site or the exosite of IDE.Consistently with their peculiar binding mode, these compounds behave as inhibitors or activators of the enzyme in a substrate-dependent manner.We made several chemical modulations on the hit structure and synthesized about 80 analogues to increase both potency and cell permeation.The mode of action of our compounds opens new avenues for the study of the function of IDE and for the design of therapeutic interventions.In the mean time, an in situ Click Chemistry experiment led to the identification of 32 ligands over 180 potential compounds. 12 compounds were resynthesised and showed inhibitory activities on the enzyme for all substrats. Co-crystallisation confirmed the binding to the catalytical site thanks to a hydroxamate function.LILLE1-Bib. Electronique (590099901) / SudocSudocFranceF

Novel non-carboxylic acid retinoids: 1,2,4-oxadiazol-5-one derivatives.

International audienceWe have successfully obtained 1,2,4-oxadiazol-5-one bioisoteres of Am580 or Tazarotene-like retinoids. In particular compound 4 displays an EC(50) of 26nM on RAR-beta

Hydroxamates: Relationships between Structure and Plasma Stability

International audienceHydroxamates are valuable tools for chemical biology as well as interesting leads for medicinal chemistry. Though many hydroxamates display nanomolar activities against metalloproteases, only three hydroxamates have reached the market, among which is the HDAC inhibitor vorinostat. Failures in development are generally attributed to lack of selectivity, toxicity or poor stability. To help medicinal chemists with respect to plasma stability, we have performed the first and preliminary study on structure-plasma stability for hydroxamates. We define some structural rules to predict or improve the plasma stability in the preclinical stage

A library of novel hydroxamic acids targeting the metallo-protease family: design, parallel synthesis and screening.

International audienceWe report here the design and parallel synthesis of 217 compounds based on a malonic-hydroxamic acid template. These compounds are obtained via a two-step solution-phase procedure. The set of diverse building-blocks used makes this strategy suitable for the search of inhibitors of various metallo-proteases and for the investigation of the biological role of new metallo-proteases. As a proof of concept, we screened this library on Neutral Aminopeptidase (APN; EC 3.4.11.2), the prototypal enzyme of the M1 family. Several submicromolar inhibitors were identified

Access to newly functionalized imidazole derivatives: efficient synthesis of novel 5-amino-2-thioimidazoles using propylphosphonic anhydride (®T3P)

International audienc